Head to Head Review: GW Pharmaceuticals PLC- (GWPH) vs. Gemphire Therapeutics (GEMP)

GW Pharmaceuticals PLC- (NASDAQ: GWPH) and Gemphire Therapeutics (NASDAQ:GEMP) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, valuation and dividends.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for GW Pharmaceuticals PLC- and Gemphire Therapeutics, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
GW Pharmaceuticals PLC- 0 1 7 0 2.88
Gemphire Therapeutics 0 0 5 0 3.00

GW Pharmaceuticals PLC- currently has a consensus price target of $152.50, suggesting a potential upside of 14.29%. Gemphire Therapeutics has a consensus price target of $24.60, suggesting a potential upside of 202.96%. Given Gemphire Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Gemphire Therapeutics is more favorable than GW Pharmaceuticals PLC-.


This table compares GW Pharmaceuticals PLC- and Gemphire Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
GW Pharmaceuticals PLC- -1,607.85% -40.42% -34.97%
Gemphire Therapeutics N/A -170.04% -120.55%

Insider & Institutional Ownership

74.6% of GW Pharmaceuticals PLC- shares are held by institutional investors. Comparatively, 32.1% of Gemphire Therapeutics shares are held by institutional investors. 5.5% of GW Pharmaceuticals PLC- shares are held by company insiders. Comparatively, 34.0% of Gemphire Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valuation & Earnings

This table compares GW Pharmaceuticals PLC- and Gemphire Therapeutics’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
GW Pharmaceuticals PLC- $11.00 million 336.85 -$166.90 million ($7.06) -18.90
Gemphire Therapeutics N/A N/A -$14.58 million ($2.90) -2.80

Gemphire Therapeutics has lower revenue, but higher earnings than GW Pharmaceuticals PLC-. GW Pharmaceuticals PLC- is trading at a lower price-to-earnings ratio than Gemphire Therapeutics, indicating that it is currently the more affordable of the two stocks.


Gemphire Therapeutics beats GW Pharmaceuticals PLC- on 7 of the 12 factors compared between the two stocks.

About GW Pharmaceuticals PLC-

GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD). The Company offers Sativex (nabiximols), which is indicated for the treatment of spasticity due to multiple sclerosis (MS). The Company operates through three segments: Commercial, Sativex Research and Development, and Pipeline Research and Development. The Commercial segment distributes and sells the Company’s commercial products. The Sativex Research and Development segment seeks to maximize the potential of Sativex through the development of new indications. The Pipeline Research and Development segment seeks to develop cannabinoid medications other than Sativex across a range of therapeutic areas using its cannabinoid technology platform.

About Gemphire Therapeutics

Gemphire Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutics to treat cardiovascular and metabolic diseases. It is developing its product candidate, gemcabene (CI-1027), which is a once-daily, oral therapy for patients who are unable to achieve normal levels of low-density lipoprotein cholesterol (LDL-C) or triglycerides with approved therapies, primarily statin therapy. Gemcabene is liver-directed and inhibits apolipoprotein C-III (apoC-III) protein in the liver and may inhibit acetyl-CoA carboxylase (ACC) in the liver. Gemcabene blocks the overall production of hepatic triglycerides and cholesterol. Gemcabene has been tested as monotherapy and in combination with statins and other drugs in over 895 subjects, across approximately 18 Phase I and Phase II clinical trials. Gemcabene is used as an adjunctive therapy to reduce LDL-C, high-sensitivity C-reactive protein (hsCRP) and triglycerides.

Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply